Global Autologous Cell Therapy Market Size, Share, Growth, Trends, and Forecast (2024 - 2031)
Global Autologous Cell Therapy Market Scope: Historical Data (2021 – 2022), Base Year (2023), Forecast Period (2024 – 2031)
Market Segmentation: By Therapy (Autologous Stem Cell Therapy, and Autologous Cellular Immunotherapies), Application (Oncology, Musculoskeletal Disorder, Blood Disorder, Autoimmune Disease, and Others), Source (Bone Marrow, Epidermis, and Others), End User (Hospitals, Research Centers, and Others), and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
Market Overview
The Global Autologous Cell Therapy Market was valued at USD 6,282.7 million in 2023 and is expected to reach USD 25,952.6 million by 2031 while growing at a CAGR of 19.4% during the forecast period (2024-2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Market Dynamics
This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global autologous cell therapy market growth. Autologous cell therapy, a form of regenerative medicine, utilizes a patient's cells for therapeutic purposes. The term "autologous" indicates that the cells come from the same individual who will receive them. Ongoing research seeks to overcome challenges and broaden the applications of this therapy.
The increasing incidence of chronic diseases and technological advancements in regenerative medicine and cell therapy are propelling significant growth in the autologous cell therapy market. Nevertheless, challenges such as the high cost of treatment and the lack of standardized protocols for cell processing and manufacturing may impede the market's expansion.
Furthermore, the global autologous cell therapy industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.
Segmentation – By Therapy Analysis
The Global Autologous Cell Therapy Market is segmented among Autologous Stem Cell Therapy, and Autologous Cellular Immunotherapies, based on Therapy. In 2023, Autologous Cellular Immunotherapies accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Segmentation – By Application Analysis
The Global Autologous Cell Therapy Market is segmented among Oncology, Musculoskeletal Disorders, Blood Disorders, Autoimmune Diseases, and Others, based on Application. In 2023, Oncology accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Global Autologous Cell Therapy Market: Regional Analysis
Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Competitive Landscape
Some of the key players operating in the market are Vericel Corporation, Pharmicell Co., Inc., Holostem Terapie Avanzate S.r.l., Lineage Cell Therapeutics, Inc., Opexa Therapeutics, BrainStorm Cell Therapeutics, Sangamo Therapeutics, Bayer AG, Daiichi Sankyo Co., Ltd, and Takeda Pharmaceutical Co., Ltd.
Table of Contents:
1. Research Methodology and Market Scope
Research Methodology
Market Scope
2. Executive Summary
3. Global Autologous Cell Therapy Market Dynamics
Drivers
Restraints
Opportunity
4. Global Autologous Cell Therapy Industry Analysis
PEST Analysis
Porter's Five Force Analysis
Recent Deals Analysis
5. Global Autologous Cell Therapy Market Segmentation, By Therapy
Global Autologous Cell Therapy Market Share Analysis, By Therapy
Global Autologous Cell Therapy Market Growth Analysis, By Therapy
Global Autologous Cell Therapy Market Trends, By Therapy
o Autologous Stem Cell Therapy
o Autologous Cellular Immunotherapies
6. Global Autologous Cell Therapy Market Segmentation, By Application
Global Autologous Cell Therapy Market Share Analysis, By Application
Global Autologous Cell Therapy Market Growth Analysis, By Application
Global Autologous Cell Therapy Market Trends, By Application
o Oncology
o Musculoskeletal Disorder
o Blood Disorder
o Autoimmune Disease
o Others
7. Global Autologous Cell Therapy Market Segmentation, By Source
Global Autologous Cell Therapy Market Share Analysis, By Source
Global Autologous Cell Therapy Market Growth Analysis, By Source
Global Autologous Cell Therapy Market Trends, By Source
o Bone Marrow
o Epidermis
o Others
8. Global Autologous Cell Therapy Market Segmentation, By End User
Global Autologous Cell Therapy Market Share Analysis, By End User
Global Autologous Cell Therapy Market Growth Analysis, By End User
Global Autologous Cell Therapy Market Trends, By End User
o Hospitals
o Research Centers
o Others
9. Global Autologous Cell Therapy Market Segmentation, By Region
Global Autologous Cell Therapy Market Share Analysis, By Region
Global Autologous Cell Therapy Market Growth Analysis, By Region
Global Autologous Cell Therapy Market Trends, By Region
o North America
o Europe
o Asia Pacific
o Latin America
o Middle East
o Africa
10. Competitive Landscape
Vericel Corporation*
o Company Overview
o Financial Performance
o Key Development/Strategies
o SWOT Analysis
Pharmicell Co., Inc.
Holostem Terapie Avanzate S.r.l.
Lineage Cell Therapeutics, Inc.
Opexa Therapeutics
BrainStorm Cell Therapeutics
Sangamo Therapeutics
Bayer AG
Daiichi Sankyo Co., Ltd
Takeda Pharmaceutical Co., Ltd
*Similar analysis will be provided for each company listed above.
